The companies aim to complete two trials by March 2021
Brits are to participate in a pilot of digital COVID-19 immunity and vaccination passports developed by Mvine and iProov, the biometric and identity technology providers.
The Mvine-iProov passport allows users to register and confirm a test result or vaccination status of a person without revealing their identity.
According to the report, the Mvine-iProov passport can be connected to existing NHS infrastructure to meet the special needs of local Public Health Directors and any general national requirements.
We’re proud to announce that the Mvine-iProov solution for #vaccinepassports is moving into live testing. Read more about our partnership with @Mvine here: https://t.co/Fkr4TmqVWI pic.twitter.com/7q4TKh7ueT
— iProov (@iProov) January 13, 2021
The Mvine-iProov passport was with a total investment of £75,000 from Innovate UK following the request for ideas announcement in April 2020.
This investment in innovation in the UK is expected to help businesses and employees get back to work, as well as enable close ones to reconnect faster and more responsibly.
We’ve reported that Pfizer-BioNTech’s COVID-19 vaccine, BNT-162b2, is expected to generate $30 billion in sales by 2026, with peak sales of $13.9 billion in 2021